Filing summary
Issuer and period: The supplied filing is Trxade Group, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, not a filing identified as Scienture Holdings, Inc. The filing reports annual results, not a standalone fourth quarter.
Business context
Trxade operates a U.S. online pharmaceutical marketplace connecting independent pharmacies with suppliers and earns transaction fees. It reported more than 10,000 pharmacy members. In October 2018, it acquired Community Specialty Pharmacy (CSP), adding specialty-pharmacy operations. Newer delivery and pharmacy-management offerings had not yet generated revenue.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $3.832 million | $2.931 million |
| Gross profit | $3.383 million | $2.931 million |
| Gross margin | 88.3% | 100.0% |
| Operating income (loss) | $(87,616) | $395,095 |
| Net income | $9,038 | $288,983 |
| Operating cash flow | $273,386 | $171,670 |
Revenue rose about 31%, while net income fell about 97%; net margin was approximately 0.2%, versus 9.9% in 2017. Higher general and administrative costs and new cost of sales associated with CSP and Integra contributed to the weaker result. The filing attributes much of the revenue increase to marketplace activity and reports $395,418 of CSP revenue after acquisition.
Cash and cash equivalents were $869,557, up from $183,914. Current assets were $1.466 million and current liabilities $860,367, yielding reported working capital of $605,710. Cash provided by operations was $273,386; investing cash use was $265,279, including the CSP acquisition; financing provided $677,536, including $800,000 from stock issuance. Total assets were $2.228 million and shareholders’ equity was $844,668, compared with a $311,933 deficit a year earlier.
Balance-sheet debt totals approximately $844,052: $321,500 classified as short-term and $522,552 long-term, including related-party debt. The contractual-obligations table instead reports debt obligations of $844,042. Operating lease commitments totaled $573,253. The company had no traditional bank credit facility and said it expected to seek additional financing. Its 2019 projected general and administrative expense and working-capital requirement was approximately $3.5 million.
Material changes, outlook and risks
- CSP was acquired for $300,000 cash, a $300,000 promissory note and warrants valued at $170,291; the company recorded $725,973 of goodwill. CSP reported a post-acquisition segment loss of $116,588.
- Management said it planned to expand the platform, customer base, marketing and operations, but gave no revenue or earnings guidance and cautioned that additional financing may be needed and may not be available on favorable terms.
- In January 2019, the company formed SyncHealth MSO with a 30% initial interest and paid $250,000; it disclosed a pathway to additional ownership. A maximum of 14,776,638 company shares could be issued to PanOptic subject to revenue covenants.
- Key risks include larger, better-funded competitors; reliance on suppliers, buying groups and major customers; pharmaceutical regulation and reimbursement changes; product, fulfillment, cybersecurity and privacy risks; financing needs; and thin OTCQB trading and potential dilution. Two customers each accounted for more than 10% of revenue in both years.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing material weaknesses including insufficient written accounting policies, manual reporting processes, inadequate segregation of duties and limited accounting resources. The auditor gave an unqualified opinion on the financial statements but did not audit internal control effectiveness.
- The filing reports a 2018 net income of $9,038 and states that the company had previously become profitable in 2017; it also notes a substantial accumulated deficit from prior years. No material pending legal proceeding was identified, and management said ordinary-course litigation was not expected to materially affect the company.
Important facts for investors to verify
- Confirm issuer identity: the filing is for Trxade Group, Inc., despite the request metadata naming Scienture Holdings, Inc.
- Reconcile the filing’s differing revenue descriptions and expense presentation: consolidated revenue is $3.832 million, while a narrative comparison cites $3.408 million, apparently the Trxade segment figure.
- Reconcile the $10 difference between debt in the contractual-obligations table and debt implied by balance-sheet classifications, and confirm debt maturities, terms and related-party balances.
- Assess CSP’s post-acquisition performance, goodwill valuation and the economics and share-dilution conditions of the SyncHealth arrangement.
- Monitor liquidity against projected spending, access to financing, customer and supplier concentration, and remediation of the disclosed internal-control weaknesses.